Engineering Chimeric Antigen Receptors for Better Recognition and Function

Engineered T cells, primarily expressing chimeric antigen receptors (CARs), have shown tremendous promise as cancer treatments. However, CAR treatment has shown efficacy in only some types of cancer, and can have serious side effects. We are working to apply our expertise in immune recognition and signaling to engineer safer and more broadly effective CARs.